share_log

Redhill Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K：外國發行人報告
SEC announcement ·  04/03 07:02
Moomoo AI 已提取核心訊息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has entered into a Securities Purchase Agreement with private investors on March 29, 2024. The agreement involves the issuance and sale of 2,144,487 American Depositary Shares (ADSs) and warrants to purchase an equivalent number of ADSs. Each ADS represents 400 ordinary shares of RedHill, with the purchase price set at $0.58289 per ADS and accompanying warrant. The warrants are exercisable at $0.75 per ADS and are valid for five years from the issuance date. The offering is expected to close on April 3, 2024, subject to customary closing conditions, and aims to raise gross proceeds of $1.25 million before offering expenses. This offering is part of a 'shelf' registration statement filed with the SEC on July 29, 2021, and declared effective on August 9, 2021. No placement agent was involved in the offering. The final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on their website.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has entered into a Securities Purchase Agreement with private investors on March 29, 2024. The agreement involves the issuance and sale of 2,144,487 American Depositary Shares (ADSs) and warrants to purchase an equivalent number of ADSs. Each ADS represents 400 ordinary shares of RedHill, with the purchase price set at $0.58289 per ADS and accompanying warrant. The warrants are exercisable at $0.75 per ADS and are valid for five years from the issuance date. The offering is expected to close on April 3, 2024, subject to customary closing conditions, and aims to raise gross proceeds of $1.25 million before offering expenses. This offering is part of a 'shelf' registration statement filed with the SEC on July 29, 2021, and declared effective on August 9, 2021. No placement agent was involved in the offering. The final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on their website.
專業生物製藥公司RedHill Biopharma Ltd. 已於2024年3月29日與私人投資者簽訂了證券購買協議。該協議涉及發行和出售2,144,487股美國存托股票（ADS）和購買等量美國存託證券的認股權證。每股ADS代表RedHill的400股普通股，收購價格定爲每股ADS和附帶的認股權證0.58289美元。認股權證的行使價格爲每份ADS0.75美元，自發行之日起五年內有效。此次發行預計將於2024年4月3日結束，但須遵守慣例成交條件，目標是在發行費用前籌集125萬美元的總收益。本次發行是2021年7月29日向美國證券交易委員會提交的 “貨架” 註冊聲明的一部分，該聲明於2021年8月9日宣佈生效。沒有配售代理人蔘與此次發行。最終的招股說明書補充文件和隨附的招股說明書將提交給美國證券交易委員會，並將在其網站上公佈。
專業生物製藥公司RedHill Biopharma Ltd. 已於2024年3月29日與私人投資者簽訂了證券購買協議。該協議涉及發行和出售2,144,487股美國存托股票（ADS）和購買等量美國存託證券的認股權證。每股ADS代表RedHill的400股普通股，收購價格定爲每股ADS和附帶的認股權證0.58289美元。認股權證的行使價格爲每份ADS0.75美元，自發行之日起五年內有效。此次發行預計將於2024年4月3日結束，但須遵守慣例成交條件，目標是在發行費用前籌集125萬美元的總收益。本次發行是2021年7月29日向美國證券交易委員會提交的 “貨架” 註冊聲明的一部分，該聲明於2021年8月9日宣佈生效。沒有配售代理人蔘與此次發行。最終的招股說明書補充文件和隨附的招股說明書將提交給美國證券交易委員會，並將在其網站上公佈。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

獨立文件3

獨立文件4

獨立文件5

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息